Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies

We carried out a multicenter dose-escalation phase I study of oral OPB-51602, a signal transducer and activator of transcription 3 phosphorylation inhibitor, in patients with relapsed or refractory hematological malignancies to evaluate the safety, maximum tolerated dose (MTD), pharmacokinetics, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogura, Michinori, Uchida, Toshiki, Terui, Yasuhito, Hayakawa, Fumihiko, Kobayashi, Yukio, Taniwaki, Masafumi, Takamatsu, Yasushi, Naoe, Tomoki, Tobinai, Kensei, Munakata, Wataru, Yamauchi, Takeshi, Kageyama, Akiko, Yuasa, Miyuki, Motoyama, Masaaki, Tsunoda, Takeshi, Hatake, Kiyohiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520642/
https://www.ncbi.nlm.nih.gov/pubmed/25912076
http://dx.doi.org/10.1111/cas.12683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520642/
https://www.ncbi.nlm.nih.gov/pubmed/25912076
http://dx.doi.org/10.1111/cas.12683

Ejemplares similares